Clinical Trial Detail

NCT ID NCT02269579
Title Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celator Pharmaceuticals
Indications

acute myeloid leukemia

myelodysplastic syndrome

acute lymphoblastic leukemia

Therapies

CPX-351

Age Groups: adult senior

No variant requirements are available.